AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10889381 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant brachytherapy (BRT)
Number of subjects: 164
Study 10889381 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant brachytherapy (no-BRT)
Number of subjects: 164
Study 8808722 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CP protocol)
Number of subjects: 30
Study 8808722 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-surgery treatment (1 and 3 months) during chemotherapy
Number of subjects: 30
Study 8808722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no malignant ovarian tumor)
Number of subjects: 30
Study 8382537 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) treatment
Number of subjects: 30
Study 3523589 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured angle beta
Number of subjects: 167
Study 3523589 — intervention group
Group type: EXPERIMENTAL
Intervention: Global impression of the operator
Number of subjects: 167
Study 29753474 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 5
Study 29753474 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg of 25(OH)D3
Number of subjects: 5
Study 29753474 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg of LPS
Number of subjects: 5
Study 29753474 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 100 μg of 25(OH)D3 and 5 μg of LPS
Number of subjects: 5
Study 29753474 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS treatment
Number of subjects: 5
Study 29753474 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D3 treatment
Number of subjects: 5
Study 29753474 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of LPS and 25(OH)D3
Number of subjects: 5
Study 26836244 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormone therapy (17β-estradiol combined with norethisterone acetate 2 mg + 1 mg/d) for 24 weeks
Number of subjects: 70
Study 26836244 — intervention group
Group type: COMPARATOR
Intervention: Transdermal hormone therapy (17β-estradiol combined with norethisterone acetate 0.05 mg + 5 mg/d) for 24 weeks
Number of subjects: 70
Study 26836244 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal women compared to premenopausal women
Number of subjects: 70
Study 26122893 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial orienting to a body site
Number of subjects: 0
Study 26122893 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar body postures
Number of subjects: 0
Study 26122893 — intervention group
Group type: EXPERIMENTAL
Intervention: Unusual body postures
Number of subjects: 0
Study 23537895 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 35
Study 23537895 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 35
Study 21486162 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy food (SF) - 2 to 3 servings per day providing ∼19 g protein and ∼36 mg isoflavones for 10 weeks
Number of subjects: 63
Study 21486162 — intervention group
Group type: COMPARATOR
Intervention: Animal food (AF) - control group
Number of subjects: 63
Study 21486162 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy food (SF)
Number of subjects: 63
Study 21486162 — intervention group
Group type: COMPARATOR
Intervention: Animal food (AF)
Number of subjects: 63
Study 18021495 — intervention group
Group type: EXPERIMENTAL
Intervention: 303 Algorithm (insulin detemir)
Number of subjects: 0
Study 18021495 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (physician-driven adjustments)
Number of subjects: 0
Study 18458383 — intervention group
Group type: EXPERIMENTAL
Intervention: rbFGF/ACS (n = 30)
Number of subjects: 58
Study 18458383 — intervention group
Group type: COMPARATOR
Intervention: Placebo (petrolatum sterile gauze, n = 28)
Number of subjects: 58
Study 15037821 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 1, 2.5, 5, 10, 20, or 40 mg once daily for 6 weeks
Number of subjects: 112
Study 15037821 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 112
Study 15037821 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 112
Study 10846808 — intervention group
Group type: EXPERIMENTAL
Intervention: Semistructured interview exploring social phobic imagery
Number of subjects: 22
Study 9169246 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (50-250 mg/day)
Number of subjects: 28
Study 9169246 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (1-5 mg/day)
Number of subjects: 28
Study 9169246 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 28
Study 9169246 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 28
Study 8230008 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (average 4.5 g daily)
Number of subjects: 34
Study 8230008 — intervention group
Group type: COMPARATOR
Intervention: Other NSAIDs (stable doses)
Number of subjects: 34
Study 3468491 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic indomethacin
Number of subjects: 0
Study 3468491 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0
Study 3468491 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 31930891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild moxibustion combined with salt-separated moxibustion; 15 min per treatment, once a day for 7 days
Number of subjects: 48
Study 31930891 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of tropisetron hydrochloride (5 mg), once a day for three days
Number of subjects: 48
Study 29934198 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (1 mg/day)
Number of subjects: 252
Study 29934198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 27411352 — intervention group
Group type: EXPERIMENTAL
Intervention: C1M
Number of subjects: 5855
Study 27411352 — intervention group
Group type: EXPERIMENTAL
Intervention: VICM
Number of subjects: 5855
Study 27411352 — intervention group
Group type: EXPERIMENTAL
Intervention: C4M
Number of subjects: 5855
Study 23884638 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-Focused Therapy (SFT)
Number of subjects: 98
Study 23884638 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 98
Study 22577908 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of potassium chloride
Number of subjects: 100
Study 22577908 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusions of potassium chloride
Number of subjects: 100
Study 20102859 — intervention group
Group type: EXPERIMENTAL
Intervention: PREMIER lifestyle intervention
Number of subjects: 809
Study 20102859 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional lifestyle modifications)
Number of subjects: 809
Study 18635470 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music
Number of subjects: 40
Study 18635470 — intervention group
Group type: COMPARATOR
Intervention: No music (Control)
Number of subjects: 40
Study 15845554 — intervention group
Group type: EXPERIMENTAL
Intervention: High demands, low control, and low support (combined)
Number of subjects: 5562
Study 15845554 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological demands, control, and social support (individual effects)
Number of subjects: 5562
Study 15845554 — intervention group
Group type: EXPERIMENTAL
Intervention: Support (DCSQ index)
Number of subjects: 5562
Study 15845554 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of psychosocial work environment
Number of subjects: 5562
Study 12455858 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) and physiotherapy
Number of subjects: 49
Study 12455858 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 49
Study 10472359 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose sequential chemotherapy (HDS) consisting of cyclophosphamide (7 gr/m2), methotrexate (8 gr/m2), vincristin (2 mg), 2 courses of carboplatin (360 mg/m2), Thiotepa (600 mg/m2), L-PAM (160 mg/m2) with stem cell support
Number of subjects: 14
Study 8738689 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal morphine hydrogel 0.2 mg/kg
Number of subjects: 26
Study 8738689 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal morphine solution 0.2 mg/kg
Number of subjects: 26
Study 8738689 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine 0.2 mg/kg
Number of subjects: 26
Study 1400703 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg)
Number of subjects: 26
Study 1400703 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (1.0 mg/kg)
Number of subjects: 26
Study 1400703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 3904805 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigason at half of the maximal dose tolerated during the clearing phase of the treatment
Number of subjects: 36
Study 3904805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3904805 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigason
Number of subjects: 36
Study 31401675 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise training (HIIT)
Number of subjects: 52
Study 30539170 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CADx) using CMDfact 4 functional diagnostics software
Number of subjects: 39
Study 30539170 — intervention group
Group type: COMPARATOR
Intervention: Traditional diagnostic methods (TRAD)
Number of subjects: 39
Study 27586548 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 3000 mg/day with weight loss diet and 400 IU vitamin E
Number of subjects: 38
Study 24698514 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitor toxicity (CNIT)
Number of subjects: 55
Study 24698514 — intervention group
Group type: COMPARATOR
Intervention: Normal allografts (control)
Number of subjects: 55
Study 24698514 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressors to CAD
Number of subjects: 55
Study 24698514 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprogressors to CAD
Number of subjects: 55
Study 22327091 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy (12 weeks, 12.5 Hz frequency and 3 mm amplitude)
Number of subjects: 41
Study 22327091 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care including medical care and social support)
Number of subjects: 41
Study 20935080 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 9
Study 20935080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 9
Study 20935080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 18830038 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly treatment with 17.5 mg risedronate
Number of subjects: 0
Study 18830038 — intervention group
Group type: COMPARATOR
Intervention: Once-daily treatment with 2.5 mg risedronate
Number of subjects: 0
Study 15716168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued covert orienting with exogenous cues (luminance change in a peripheral box)
Number of subjects: 132
Study 15716168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued covert orienting with endogenous cues (central arrow)
Number of subjects: 132
Study 15716168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued covert orienting with endogenous cues (central word)
Number of subjects: 132
Study 15716168 — intervention group
Group type: COMPARATOR
Intervention: Control group (typically developing children)
Number of subjects: 132
Study 11833749 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT
Number of subjects: 83
Study 11833749 — intervention group
Group type: COMPARATOR
Intervention: MCT/LCT
Number of subjects: 83
Study 10517170 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery during the follicular phase (days 0-14)
Number of subjects: 248
Study 10517170 — intervention group
Group type: COMPARATOR
Intervention: Surgery during the luteal phase (days 15-32)
Number of subjects: 248
Study 8559485 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (500 micrograms thrice weekly for 3 months, then 200 micrograms thrice weekly for the next 3 months)
Number of subjects: 10
Study 8559485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1780077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (200 mg b.i.d.) combined with low-dose aspirin (25 mg b.i.d.)
Number of subjects: 88
Study 1780077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 6358451 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional periodontal treatment with adjunctive metronidazole therapy
Number of subjects: 0
Study 6358451 — intervention group
Group type: COMPARATOR
Intervention: Conventional periodontal treatment without adjunctive metronidazole therapy (placebo)
Number of subjects: 0
Study 31074484 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobehavioral therapy with orthopedic manual physical therapy
Number of subjects: 50
Study 31074484 — intervention group
Group type: COMPARATOR
Intervention: Biobehavioral therapy only
Number of subjects: 50
Study 29475737 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT+D (Docetaxel) for high-volume disease
Number of subjects: 1175
Study 29475737 — intervention group
Group type: COMPARATOR
Intervention: ADT alone for low-volume disease
Number of subjects: 1175
Study 26467373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg orally for 2 weeks before and 12 weeks after surgery)
Number of subjects: 60
Study 26467373 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (50 mg orally for 2 weeks before and 12 weeks after surgery)
Number of subjects: 60
Study 26467373 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (combined data)
Number of subjects: 60
Study 25345429 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT-1 (600 mg thioctic acid)
Number of subjects: 72
Study 25345429 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT-2 (600 mg thioctic acid)
Number of subjects: 72
Study 25345429 — intervention group
Group type: COMPARATOR
Intervention: Reference (Thioctacid® HR)
Number of subjects: 72
Study 25345429 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT-2
Number of subjects: 72
Study 22851967 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial branch blocks with local anesthetic alone
Number of subjects: 100
Study 22851967 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial branch blocks with local anesthetic and steroids
Number of subjects: 100
Study 20136553 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE)
Number of subjects: 6461
Study 20136553 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 6461
Study 20136553 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 6461
Study 20136553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6461
Study 17257477 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75-325 mg/day)
Number of subjects: 0
Study 17257477 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 0
Study 17257477 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 0
Study 17257477 — intervention group
Group type: COMPARATOR
Intervention: Other antiplatelet agents (e.g., clopidogrel)
Number of subjects: 0
Study 15797227 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 94
Study 15797227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 12480784 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperintense lesions (HL) in subcortical gray matter (thalamus and caudate) and associated white matter tracts (internal/external capsule)
Number of subjects: 154
Study 12480784 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperintense lesions (HL) in both gray and white matter
Number of subjects: 154
Study 9653409 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (residents who participated in the teaching skills course)
Number of subjects: 2
Study 9653409 — intervention group
Group type: COMPARATOR
Intervention: Control group (residents who did not participate in the teaching skills course)
Number of subjects: 2
Study 9653409 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 2
Study 9653409 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study 8129609 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride (100 mg) administered twice a day intravenously for 4 days, followed by oral ranitidine hydrochloride (150 mg) administered twice a day for 5 days (n = 11)
Number of subjects: 24
Study 8129609 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (n = 13)
Number of subjects: 24
Study 8129609 — intervention group
Group type: COMPARATOR
Intervention: Control patients (n = 13)
Number of subjects: 24
Study 2697240 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 2697240 — intervention group
Group type: COMPARATOR
Intervention: Thiopental/Isuflurane
Number of subjects: 60
Study 4609532 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of marihuana sample B
Number of subjects: 33
Study 4609532 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of marihuana sample A
Number of subjects: 33
Study 4609532 — intervention group
Group type: COMPARATOR
Intervention: 500 mg of marihuana sample C
Number of subjects: 33
Study 4609532 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta(9)-THC administered to human subjects and laboratory animals
Number of subjects: 33
Study 30540353 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful discontinuation of antipsychotic medication regimens
Number of subjects: 0
Study 30540353 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27588891 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Training and Nutrition (PTN) group
Number of subjects: 80
Study 27588891 — intervention group
Group type: COMPARATOR
Intervention: Social Support (SOSU) group
Number of subjects: 80
Study 25223963 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced exercise (n=30)
Number of subjects: 59
Study 25223963 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity exercise (n=29)
Number of subjects: 59
Study 24103648 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based quality improvement plus facilitation intervention
Number of subjects: 12
Study 24103648 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 12
Study 22128655 — intervention group
Group type: EXPERIMENTAL
Intervention: U.S. Navy Sexual Assault Intervention Training (SAIT) program
Number of subjects: 550
Study 22128655 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 550
Study 19780737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy with compressed carbon dioxide through a cryoprobe placed on the cervix
Number of subjects: 85
Study 19780737 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 85
Study 16427211 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage hormone therapy (HT) initiated after initial treatment
Number of subjects: 247
Study 16427211 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage hormone therapy (HT) for patients with DM absent
Number of subjects: 247
Study 15562184 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified low fat diet inclusive of 30 g of walnuts per day
Number of subjects: 58
Study 15562184 — intervention group
Group type: COMPARATOR
Intervention: Modified low fat diet
Number of subjects: 58
Study 15562184 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet
Number of subjects: 58
Study 15562184 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut group
Number of subjects: 58
Study 15562184 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 58
Study 11743411 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth saline-filled prosthesis
Number of subjects: 20
Study 11743411 — intervention group
Group type: COMPARATOR
Intervention: Textured saline-filled prosthesis
Number of subjects: 20
Study 11743411 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient satisfaction
Number of subjects: 20
Study 9402166 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with hematopoietic progenitor cell support (doxorubicin 75 mg/m2, cyclophosphamide 6000 mg/m2, etoposide 800 mg/m2, carboplatin 900 mg/m2, G-CSF 5 microg/kg/d)
Number of subjects: 30
Study 8517510 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adrenaline (10 mg every five minutes)
Number of subjects: 40
Study 8517510 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of adrenaline (1 mg every five minutes)
Number of subjects: 40
Study 3318052 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenothiazine (thiethylperazine)
Number of subjects: 132
Study 3318052 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of thiethylperazine and antihistaminic (diphenhydramine)
Number of subjects: 132
Study 3318052 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of thiethylperazine and tricyclic antidepressant (amitriptyline)
Number of subjects: 132
Study 29444618 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 24
Study 29444618 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 24
Study 29444618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29489103 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-paravertebral anesthesia (KSPA)
Number of subjects: 67
Study 29489103 — intervention group
Group type: COMPARATOR
Intervention: Combined spinal-epidural anesthesia (CSEA)
Number of subjects: 67
Study 24719063 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical liposomal Rose Bengal (LRB) gel followed by intense pulsed light (IPL) treatment
Number of subjects: 15
Study 24719063 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel followed by intense pulsed light (IPL) treatment
Number of subjects: 15